Title: Supplementary table 1.

Caption: Additional pharmacokinetic parameters of pictilisib

Title: Supplementary table 2.

Caption: Details of patients who achieved a partial response by RECIST, GCIG CA125 or 18F-FDG-PET EORTC criteria.

Title: Supplementary figure 1.

Caption: Changes in insulin and glucose levels with pictilisib

Plots of fold change (i.e. ratios of 1 hour-post- over pre-treatment) in plasma levels of insulin (left panel) and glucose (right panel) on cycle 1 day 1 following treatment with different doses of pictilisib (Represented for each dose level are the geometric mean and the associated 95% confidence intervals of the ratios).

Title: Supplementary figure 2.

Caption: Waterfall plot of changes in18F-FDG-PET SUVmax grouped according to pictilisib AUC as assessed by an independent review facility.

Title: Supplementary figure 3.

Caption: Details of a 49 year old patient with platinum-refractory metastatic ovarian cancer and 5 previous lines of chemotherapy treated with oral pictilisib at 100mg once-daily on days 1-21 every 28 days. Following pictilisib treatment, there was a 56% reduction in tumoral phospho-S6 levels (A), 30% reduction in mean SUVmax in her subcapsular liver metastases [indicated in blue arrows] (B), a decrease in serum CA125 from 1214 U/ml to 400 U/ml (C) and stable disease by RECIST for 4 months. Biomarker analyses revealed the presence of PIK3CA amplification by fluorescence in-situ hybridization (with high polysomy and >60% of tumor cells having 4 copies of PIK3CA) and loss of PTEN by immunohistochemistry.

Title: Supplementary figure 4.

Caption: Association between severity of treatment-related rash and steady-state exposure (day 15 AUC0-24) to pictilisib. (Gr=Grade).